[go: up one dir, main page]

AR126654A1 - Péptidos y métodos para el tratamiento de neuromielitis óptica - Google Patents

Péptidos y métodos para el tratamiento de neuromielitis óptica

Info

Publication number
AR126654A1
AR126654A1 ARP220101690A ARP220101690A AR126654A1 AR 126654 A1 AR126654 A1 AR 126654A1 AR P220101690 A ARP220101690 A AR P220101690A AR P220101690 A ARP220101690 A AR P220101690A AR 126654 A1 AR126654 A1 AR 126654A1
Authority
AR
Argentina
Prior art keywords
sequence
epitope
aqp4
treatment
aquaporin
Prior art date
Application number
ARP220101690A
Other languages
English (en)
Inventor
Milos Erak
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of AR126654A1 publication Critical patent/AR126654A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se relaciona con péptidos inmunogénicos derivados de Acuaporina 4 (AQP4) para uso en el tratamiento de Trastornos del Espectro de Neuromielitis Óptica (NMOSD) y con la generación de células T CD4+ citolíticas o células NKT contra células presentadoras de antígeno que presentan la secuencia de un epítope de AQP4 de tipo salvaje. Reivindicación 1: Un péptido inmunogénico aislado con una longitud de entre 12 y 50 aminoácidos, comprendiendo dicho péptido inmunogénico: un motivo de oxidorreductasa con la secuencia Zₘ-[CST]-Xₙ-C- o Zₘ-C-Xₙ-[CST]-, en donde n es un entero elegido de: 2, 0, 1 o 3, en donde m es un entero seleccionado de 1, 0, 2 o 3, en donde X es cualquier aminoácido, en donde Z es cualquier aminoácido, en la cual C representa cisteína, S para serina, T para treonina; y un epítope de células T del antígeno Acuaporina 4 (AQP4); en donde dicho motivo de oxidorreductasa y dicho epítope están separados por una secuencia enlazadora de entre 0 a 7 aminoácidos, preferiblemente en donde dicho epítope comprende una secuencia seleccionada del grupo que consiste en SEQ ID Nº 1 a 135.
ARP220101690A 2021-06-29 2022-06-28 Péptidos y métodos para el tratamiento de neuromielitis óptica AR126654A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21182499 2021-06-29

Publications (1)

Publication Number Publication Date
AR126654A1 true AR126654A1 (es) 2023-11-01

Family

ID=76999600

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101690A AR126654A1 (es) 2021-06-29 2022-06-28 Péptidos y métodos para el tratamiento de neuromielitis óptica

Country Status (15)

Country Link
US (1) US20240228558A9 (es)
EP (1) EP4362972A1 (es)
JP (1) JP2024527274A (es)
KR (1) KR20240025673A (es)
CN (1) CN117729932A (es)
AR (1) AR126654A1 (es)
AU (1) AU2022304222A1 (es)
CA (1) CA3222570A1 (es)
CO (1) CO2024000603A2 (es)
CU (1) CU20230054A7 (es)
IL (1) IL309258A (es)
MX (1) MX2023015534A (es)
PE (1) PE20250119A1 (es)
TW (1) TW202306971A (es)
WO (1) WO2023275108A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202530251A (zh) * 2023-09-22 2025-08-01 德國符茲堡大學 ＭＨＣ Ｉｂ媒介之水通道蛋白４（ＡＱＰ４）特異性免疫抑制作為用於ＮＭＯ之新穎治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2059256T3 (pl) 2006-08-11 2017-02-28 Life Sciences Research Partners Vzw Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
EP2249855B1 (en) * 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic peptides and their use in transplantation
ES2650236T3 (es) 2008-02-14 2018-01-17 Life Sciences Research Partners Vzw Linfocitos T CD4+ con propiedades citolíticas
DE11787873T1 (de) 2010-11-25 2013-12-12 Imnate Sarl Immugene Peptide zur Verwendung bei der Vorbeugung und/oder Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Immunreaktionen auf Allofaktoren, allergischen Erkrankungen, Tumoren, Transplantatabstossungen und Immunreaktionen auf virale Vektoren
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
JP7320947B2 (ja) 2016-04-19 2023-08-04 アンシス・エスア 新規な免疫原性ＣＤ１ｄ結合ペプチド
WO2017196432A1 (en) * 2016-05-12 2017-11-16 La Jolla Institute For Allergy And Immunology Compositions and methods for diagnosing and treating neurodegenerative disease
WO2018188730A1 (en) 2017-04-11 2018-10-18 Biontech Rna Pharmaceuticals Gmbh Rna for treatment of autoimmune diseases
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
CN114746111A (zh) * 2019-11-27 2022-07-12 易姆赛斯股份公司 用于对糖尿病患者进行分层的方法
EP3915575A1 (en) * 2020-05-29 2021-12-01 Imnate Sarl Vaccine formulations

Also Published As

Publication number Publication date
EP4362972A1 (en) 2024-05-08
WO2023275108A1 (en) 2023-01-05
AU2022304222A9 (en) 2024-01-11
CA3222570A1 (en) 2023-01-05
AU2022304222A1 (en) 2023-12-14
IL309258A (en) 2024-02-01
KR20240025673A (ko) 2024-02-27
CN117729932A (zh) 2024-03-19
TW202306971A (zh) 2023-02-16
CO2024000603A2 (es) 2024-05-10
US20240228558A9 (en) 2024-07-11
JP2024527274A (ja) 2024-07-24
US20240132556A1 (en) 2024-04-25
MX2023015534A (es) 2024-02-15
PE20250119A1 (es) 2025-01-16
CU20230054A7 (es) 2024-08-15

Similar Documents

Publication Publication Date Title
PE20240491A1 (es) Peptidos y metodos para el tratamiento de esclerosis multiple
CY1125492T1 (el) Πεγκυλιωμενα λιποσωματα για χορηγηση rna το οποιο κωδικοποιει ενα ανοσογονο
CY1110051T1 (el) Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ii
CL2023000426A1 (es) Neoantígenos ras y usos de los mismos
PE20210376A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
CO2020015707A2 (es) Casetes de expresión de α-glucosidasa de ácido optimizado con codón y métodos de uso del mismo
BRPI9912175A (pt) peptídios de antígeno cd4-cdr2, composição farmacêutica compreendendo os mesmos bem como uso da mesma
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
PE20191529A1 (es) Peptidos y metodos para el tratamiento de diabetes
ES2138086T3 (es) Constructo de peptido sintetico compuesto que provoca anticuerpos neutralizantes y linfocitos t citotoxicos contra hiv.
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
AR126654A1 (es) Péptidos y métodos para el tratamiento de neuromielitis óptica
RU2013131089A (ru) Пептиды тем8 и содержащие их вакцины
PE20181897A1 (es) Inmunoterapia contra el melanoma y otros tipos de cancer
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
MX2022005704A (es) Peptidos antigenicos para la prevencion y el tratamiento de malignidad de celulas b.
AR123187A1 (es) Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer
AR125379A1 (es) Un fab anti-tslp con estabilidad mejorada
MX2023014654A (es) Un conjugado.
CL2025001619A1 (es) Nanopellets de proteína para la vacunación de peces o teleósteos y crustáceos
CN101370513B (zh) 由肿瘤抗原衍生的优化隐蔽性肽组成的免疫原性多肽及其用途
MX2024011785A (es) Peptidos antigenicos para la prevencion y el tratamiento del cancer
AR084095A1 (es) Peptidos tomm34 y vacunas que los incluyen
AR123634A1 (es) Péptidos amidados y sus contrapartes desamidadas representadas mediante hla-a*02 para su uso en inmunoterapia contra diferentes tipos de cánceres
BR112023017163A2 (pt) Proteína transportadora para antígeno peptídico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal